oleclumab,ceralasertib,durvalumab,olaparib,danvatirsen,trastuzumab deruxtecan,cediranib,vistusertib
merck,astrazeneca,daiichi sankyo
['hudson']
hudson #aacr23 with data, worked with iom for guidelines to publish the first version in 2003, now on it's 5th edition. hundreds of volunteers help keep recommendations current.
Business development, marketing and sales professional in the life sciences, cancer diagnostics, and genomics fields. Blog: https://t.co/IeMzCogxlt. Opinions are my own.